Teva Pharmaceutical (TEVA) Receives FDA Approval for DuoNeb(R) Inhalation Solution
More News related to TEVA
- BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
- Teva Pharma (TEVA) Extends Oral Laquinimod Marketing and Distribution Rights to Nordic and Baltic Regions
- Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions
- Teva Pharma (TEVA) Settles with Ven-A-Care; To Record Charge of $315M for Q409
- Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced it has received final approval from the U.S. FDA for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Dey's bronchodilator, DuoNeb(R) Inhalation Solution, 3 mg and 0.5 mg. Teva said it expects to begin shipping the product immediately.
Based on IMS sales data, the brand product had annual sales of about $265 million in the United States for the twelve months ended September 30, 2007.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories.
Related Categories
FDAStocks Mentioned
+0.18Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
